Description: Lurasidone is a new atypical antipsychotic. I is also approved for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults when used alone or in combination with lithium or valproate. Lurasidone acts as an antagonist of the following sites: α1-adrenergic receptor (Ki = 48 nM); α2A-adrenergic receptor (Ki = 1.6 nM); α2C-adrenergic receptor (Ki = 10.8 nM); D1 receptor (Ki = 262 nM); D2 receptor (Ki = 1.7 nM); 5-HT2A receptor (Ki = 2.0 nM); 5-HT2C receptor (Ki = 415 nM); 5-HT7 receptor (Ki = 0.5 nM). And as a partial agonist of the following sites: 5-HT1A receptor (Ki = 6.8 nM).